*4.3. Genotyping—Validation Phase*

In total, 42 genetic variants were selected for the validation phase and assessed using commercially provided competitive allele specific PCR (KASP™) genotyping (LGC Genomics, Hoddesdon, UK) in DNA samples from 802 breast cancer patients. Primers and probes were designed by the service provider. 10% of the samples were analyzed in duplicates for the purpose of the quality control. The genotyping concordance between duplicate samples exceeded 99%.
